JAMES CHO: Open Payments
NPI 1376706754 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$35,156 in 277 payments from 22 companies in 2025. Trend: 2023 $50,386 · 2024 $26,346 · 2025 $35,156
Honoraria: $22,075Food & beverage: $6,062Speaker / faculty: $3,575Travel & lodging: $3,444
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 58 | $26,668 |
| ABBVIE INC. | 14 | $4,046 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $786 |
| Alkermes, Inc. | 15 | $460 |
| Axsome Therapeutics, Inc. | 20 | $438 |
| Otsuka America Pharmaceutical, Inc. | 16 | $421 |
| Corium, LLC | 25 | $403 |
| Teva Pharmaceuticals USA, Inc. | 9 | $377 |
| E.R. Squibb & Sons, L.L.C. | 13 | $318 |
| Neurocrine BioSciences, Inc. | 19 | $264 |
Products named: Qelbree, VRAYLAR, CAPLYTA, REXULTI, Azstarys, Auvelity, ARISTADA, COBENFY.
Industry payments across MO — which companies pay providers there.
